Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate (Q34880994)

5 August 2017

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate (English)

1 reference

5 August 2017

0 references

0 references

1 reference

1 reference

10

Robert J Lutz

1 reference

5 August 2017

Gail D Lewis Phillips

1

1 reference

5 August 2017

Guangmin Li

2

1 reference

5 August 2017

Debra L Dugger

3

1 reference

5 August 2017

Lisa M Crocker

4

1 reference

5 August 2017

Kathryn L Parsons

5

1 reference

5 August 2017

Elaine Mai

6

1 reference

5 August 2017

Walter A Blättler

7

1 reference

5 August 2017

John M Lambert

8

1 reference

5 August 2017

Ravi V J Chari

9

1 reference

5 August 2017

Wai Lee T Wong

11

1 reference

5 August 2017

Frederic S Jacobson

12

1 reference

5 August 2017

Hartmut Koeppen

13

1 reference

5 August 2017

Ralph H Schwall

14

1 reference

5 August 2017

Sara R Kenkare-Mitra

15

1 reference

5 August 2017

Susan D Spencer

16

1 reference

5 August 2017

Mark X Sliwkowski

17

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

5 August 2017

1 reference

5 August 2017

68

1 reference

5 August 2017

9280-9290

1 reference

5 August 2017

22

1 reference

describes a project that uses

5 August 2017

BT-474 EEI

0 references

cites work

Antimitotic Activity of the Potent Tumor Inhibitor Maytansine

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Progress in immunoconjugate cancer therapeutics

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Arming antibodies: prospects and challenges for immunoconjugates

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Drug-conjugated monoclonal antibodies for the treatment of cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Trastuzumab--mechanism of action and use in clinical practice

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Untangling the ErbB signalling network

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Arming antibodies for cancer therapy

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/0008-5472.CAN-08-1776

Identifiers

DOI

10.1158/0008-5472.CAN-08-1776

1 reference

5 August 2017

1 reference